FCFernanda Pereira Delgado Costa

Fernanda Pereira Delgado Costa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernanda Pereira Delgado Costa has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic alternatives with mouthwashes for management oral mucositis: an integrative review

    by Fernanda Pereira Delgado Costa, Maria Luisa Leandro de Souza Dias, Pedro Henrique Gonçalves Ferreira, Karla Emília de Sá Rodrigues, Lucas Guimarães Abreu, Tarcília Aparecida Silva, Denise Vieira Travassos

    Objective: The aim of this study was to conduct an integrative review to assess the efficacy of the mouthwashes recommended for the prevention and treatment of Oral mucositis (OM) and oropharyngeal mucositis (OPM) in patients undergoing cancer treatment. Method: The research question was formulated based on the PICOS strategy: “Are chlorhexidine, allopurinol, benzydamine and propolis mouthwashes effective in preventing and treating OM and OPM in patients undergoing cancer treatment?” Searches were performed in PubMed, Embase, Scopus, Web of Science, OpenGrey and Google Scholar, without publication year or language restrictions. Randomized clinical trials comparing the use of chlorhexidine, allopurinol, benzydamine and propolis with a control group or a group that did not undergo any intervention were included. The retrieved articles were analyzed and selected by two reviewers and disagreements were resolved by consultation with a third reviewer. Results: After evaluation of the works, 13 of 1183 articles were selected. Mouthwashes containing propolis and benzydamine mouthwashes were promising and effective in the management of mucositis while chlorhexidine or allopurinol did not provide satisfactory results. Conclusion: Mouthwashes could be an alternative for treatment or preventing oral mucositis in cancer patients. Services could consider the possibility of incorporating these medications since, in most cases, they are low cost and do not require specialized staff in their use.

  • USE OF CYTOLOGICAL SMEAR AND CELL BLOCK TECHNIQUE FOR THE DIAGNOSIS OF PLASMA CELL MYELOMA INFILTRATION IN THE MANDIBLE

    by Fernanda Aragão Felix, Ana Carolina Velasco Pondé de Sena, Thalita Soares Tavares, Denise Vieira Travassos, Fernanda Pereira Delgado Costa, Ricardo Alves de Mesquita, Tarcília Aparecida da Silva

  • Leukaemic infiltration in the oral and maxillofacial region: An update

    by Ana Carolina Velasco Pondé de Sena, José Alcides Almeida de Arruda, Fernanda Pereira Delgado Costa, Ana Paula Vilaça Lemos, Fabiana Maria Kakehasi, Denise Vieira Travassos, Lucas Guimarães Abreu, Felipe Paiva Fonseca, Ricardo Alves Mesquita, Tarcília Aparecida Silva

    Background: The purpose of this study was to integrate the available data published on leukaemic infiltration in the oral and maxillofacial region into a comprehensive analysis of its clinical manifestations, imaginological characteristics, management and survival.Materials and methods: An electronic search with no publication date restriction was undertaken in October 2020 in the following databases: PubMed, Web of Science, Scopus and Embase. Overall survival was calculated by survival analysis with the Kaplan‐Meier test. A critical appraisal of included articles was performed using the Joanna Briggs Institute tool.Results: A total of 63 studies including 68 patients were selected for data extraction. The most common haematologic diagnosis was acute myeloid leukaemia (47%). The most affected individuals were 40 to 49 years old (20.9%). The male‐to‐female ratio was 1.2:1. The gingiva was the most affected site (37%). Swelling/mass/oedema (33.7%) and enlargement/hyperplasia/hypertrophy (25.5%) were the main clinical findings. Osteolytic lesions with bone destruction were the main imaginological characteristics among the reported cases. Follow‐up was available for 36 patients. Overall, within the 21‐month follow‐up, the survival probability dropped to 14.3%.Conclusion: A considerable number of studies reported oral manifestations mainly in individuals with the acute form of leukaemia. Children and adults were affected, but the fifth decade of life was the most common. Dentists should be vigilant since these manifestations may be important for a diagnosis and for the monitoring of the treatment response and recurrence of haematological neoplasia.


  • Open Access

    Safety protocols for dental care during the COVID-19 pandemic: the experience of a Brazilian hospital service

    by Alessandra Figueiredo Souza, José Alcides Almeida de Arruda, Fernanda Pereira Delgado Costa, Larissa Marques Bemquerer, Wagner Henriques Castro, Felipe Eduardo Baires Campos, Fabiana Maria Kakehasi, Denise Vieira Travassos, Tarcília Aparecida Silva

    The coronavirus disease (COVID-19) has been prioritized in relation to other illnesses considered critical, such as cancer, cardiovascular diseases/stroke, diabetes, and autoimmune diseases. The management of patients with these diseases involves dental care to reduce systemic complications caused by odontogenic infections, and/or to treat oral manifestations of systemic comorbidities. In this regard, the dental care of these individuals must be guaranteed during the pandemic. Although a high risk of exposure to and catching of COVID-19 is expected to befall dental professionals, biosafety guidelines reduce the likelihood of infection. Thus, the current scenario poses challenges, and offers decision-making approaches and tools that facilitate the management of individuals with oral manifestations of chronic and/or critical diseases, using hospital-based services. This article presents an overview for hospital service providers who are at the forefront of COVID-19 care, including a secure protocol, and clinical guidelines based on the experience of the Hospital das Clínicas in Belo Horizonte, a public referral service, supported by the Brazilian National Health System.